JAC Advance Access originally published online on November 18, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (2002) 50, 775-777
© 2002 The British Society for Antimicrobial Chemotherapy
Leading articles |
Resistance surveillance studies—comparability of results and quality assurance of methods
1 Department of Clinical Microbiology, Central Hospital, S-351 85 Växjö, Sweden; 2 Clinical Microbiology and Public Health Laboratory, Addenbrooke’s Hospital, Hills Road, Cambridge CB2 2QW, UK
Keywords: surveillance, EARSS, antimicrobial, resistance
| The first 150 words of the full text of this article appear below. |
Surveillance of antimicrobial resistance currently has a high profile. One surveillance system with wide representation in Europe is the European Antimicrobial Resistance Surveillance System (EARSS). The paper by Bronzwaer et al.1 describes an external quality assessment (EQA) exercise undertaken as part of the EARSS programme and prompts comment on comparability of susceptibility testing methods and breakpoints and quality assurance of resistance surveillance studies in general.
Surveillance of antimicrobial resistance is generally considered to be necessary for providing local data for selection of empirical therapy, for assessing the scale of the resistance problem at a local, national or international level, for monitoring changes in resistance rates, for detecting the emergence and spread of new resistances, and for providing a measure of the effectiveness of any interventions aimed at reducing resistance.2–6 It can also provide an opportunity for improving the quality of susceptibility testing among those taking part in the surveillance.7,8 The
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. A. Pfaller, D. J. Diekema, M. G. Rinaldi, R. Barnes, B. Hu, A. V. Veselov, N. Tiraboschi, E. Nagy, D. L. Gibbs, and the Global Antifungal Surveillance Group Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-Year Analysis of Susceptibilities of Candida and Other Yeast Species to Fluconazole and Voriconazole by Standardized Disk Diffusion Testing J. Clin. Microbiol., December 1, 2005; 43(12): 5848 - 5859. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Pfaller, L. Boyken, S. A. Messer, S. Tendolkar, R. J. Hollis, and D. J. Diekema Comparison of Results of Voriconazole Disk Diffusion Testing for Candida Species with Results from a Central Reference Laboratory in the ARTEMIS Global Antifungal Surveillance Program J. Clin. Microbiol., October 1, 2005; 43(10): 5208 - 5213. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Morrissey, M. Robbins, L. Viljoen, and D. F. J. Brown Antimicrobial susceptibility of community-acquired respiratory tract pathogens in the UK during 2002/3 determined locally and centrally by BSAC methods J. Antimicrob. Chemother., February 1, 2005; 55(2): 200 - 208. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Bywater, H. Deluyker, E. Deroover, A. de Jong, H. Marion, M. McConville, T. Rowan, T. Shryock, D. Shuster, V. Thomas, et al. A European survey of antimicrobial susceptibility among zoonotic and commensal bacteria isolated from food-producing animals J. Antimicrob. Chemother., October 1, 2004; 54(4): 744 - 754. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Pfaller, K. C. Hazen, S. A. Messer, L. Boyken, S. Tendolkar, R. J. Hollis, and D. J. Diekema Comparison of Results of Fluconazole Disk Diffusion Testing for Candida Species with Results from a Central Reference Laboratory in the ARTEMIS Global Antifungal Surveillance Program J. Clin. Microbiol., August 1, 2004; 42(8): 3607 - 3612. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. M Lomaestro Resistance to Linezolid. Are We Surprised? How Hard Should We Look? Ann. Pharmacother., June 1, 2003; 37(6): 909 - 911. [Full Text] [PDF]
|
|